Wang Xiaolin 4
4 · Revolution Medicines, Inc. · Filed Mar 3, 2026
Insider Transaction Report
Form 4
Wang Xiaolin
See Remarks
Transactions
- Award
Common Stock
[F1][F2]2026-03-01+15,100→ 118,073 total - Award
Stock Option (Right to Buy)
[F3]2026-03-01+34,000→ 34,000 totalExercise: $102.02Exp: 2036-02-28→ Common Stock (34,000 underlying)
Footnotes (3)
- [F1]Includes 54,464 restricted stock units.
- [F2]Includes 652 shares acquired under the Issuer's Employee Stock Purchase Plan on May 31, 2025.
- [F3]One forty-eighth (1/48th) of the shares initially subject to the option will vest on each monthly anniversary measured from March 1, 2026 (the "Vesting Commencement Date"), so that 100% of the shares subject to the option will be fully vested and exercisable as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date.
Signature
/s/ Jack Anders, as Attorney-in-fact for Xiaolin Wang|2026-03-03